GHP Family Pharmacy Customer Service 100 N. Academy Ave. Danville, PA 17822



Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com

SOLIQUA and XULTOPHY (GLP-1 receptor agonist/insulin combinations) PRIOR AUTHORIZATION FORM (form effective 1/1/20)

Prior authorization guidelines for Hypoglycemics, Insulin and Related Agents and Quantity Limits/Daily Dose Limits are available on Geisinger Health Plan's website at https://healthplan.geisinger.org/pharmacy/pharmacy/pharmacy/strip=true&style=OneGeisinger

| New request Renewal request | total # of pages: | Prescriber name: | | | | | | |
|---|----------------------------|------------------|---|------------------------------|------------|-------------------|-------------------|--|
| Name of office contact: | | Specialty: | | | | | | |
| Contact's phone number: | | NPI: | | | | State license #: | | |
| LTC facility contact/phone: | | Street address: | | | | | | |
| Beneficiary name: | | Suite #: | Suite #: City/state/zip: | | | | | |
| Beneficiary ID#: DOB: | | Phone: | | | | Fax: | | |
| | CLINICAL I | NFORMAT | ION | | | I | | |
| Drug requested: | Soliqua | Zultophy | | | □ | | | |
| Directions: | | | Quanti | | | ty: | Refills: | |
| Diagnosis <u>(submit documentation)</u> : | | | | DX code (<u>required</u>): | | | | |
| Does the beneficiary have a diagnosis of type 2 diabetes? | | | Yes – Submit documentation of diagnosis. No – Submit medical literature supporting the use of the requested medication for the beneficiary's diagnosis. | | | | | |
| Please provide the beneficiary's Hemoglobin A1c (HbA1c): | | | HbA1c: | | | | | |
| Is the beneficiary currently taking maximum tolerated doses of metformin? | | | Yes No | | | | | |
| If not currently taking metformin, does the beneficiary have a history of a contraindication to or intolerance to maximum tolerated doses of metformin? | | | YesSubmit documentation of treatment regimen triedNoand contraindication or intolerance. | | | | | |
| Did the beneficiary fail to achieve glycemic control with basal insulin (e.g., Lantus, Levemir) and/or a GLP-1 receptor agonist (e.g., Byetta, Bydureon, Trulicity, Victoza) as evidenced by the beneficiary's HbA1c? | | | ☐ Yes Submit documentation of treatment regimen ☐ No tried | | | | | |
| Will the requested agent be used in combination with any other product containing a GLP-1 receptor agonist? | | | □ Yes □ No | | | | | |
| Please submit to PromptPA <u>https://ghp.pr</u> documentation. | omptpa.com OR fax to Geisi | inger Health | Plan at 570 |)-271-56 | 510 the co | mpleted form with | required clinical | |
| Prescriber Signature | | | | | ח | ate [.] | | |

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.